OncoSwitch featured in Science Times
Science Times profiles founder Malika Gallyamova and how OncoSwitch is turning AI-designed DNA switches into a platform for safer gene therapy.
Science Times has published a profile of OncoSwitch founder and CEO Malika Gallyamova, covering her path into synthetic biology and the company she is building around AI-designed DNA switches.
What the article covers
- How OncoSwitch combines physics-informed machine learning with massively parallel reporter assays (MPRA) to design compact regulatory DNA elements.
- Why those switches are built to stay silent in healthy cells and activate in tumor cells, so cell and gene therapies such as AAV, LNP and CAR-T constructs can be controlled without changing the core payload.
- The company's current stage: a computational prototype is complete and the team is moving into prospective biological validation, starting with hepatocellular carcinoma models.
- The team, including co-founder and CSO Nadav Ahituv of UCSF.
Malika is clear about where the company stands: "this is an early-stage platform."